Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P.

Ann Intern Med. 1998 Feb 15;128(4):253-61.

PMID:
9471927
2.

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.

Ann Intern Med. 1999 Dec 21;131(12):935-42.

PMID:
10610644
3.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
4.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
5.

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78.

PMID:
8833208
6.

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.

PMID:
11894721
7.

Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.

Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL; fracture intervention trial.

Diabetes Care. 2004 Jul;27(7):1547-53.

PMID:
15220226
8.

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd.

Am J Med. 1996 Nov;101(5):488-501.

PMID:
8948272
9.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.

N Engl J Med. 1998 Feb 19;338(8):485-92.

10.

Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Pols HA, Felsenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B.

Osteoporos Int. 1999;9(5):461-8.

PMID:
10550467
11.
12.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

13.

Osteoporosis prevention clinical study program.

Delmas P, Gimona A.

Eur J Obstet Gynecol Reprod Biol. 1996 Apr;64 Suppl:S39-45.

PMID:
8732473
14.

The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.

Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.

J Bone Miner Metab. 2009;27(4):471-8. doi: 10.1007/s00774-009-0057-7. Epub 2009 Apr 3.

PMID:
19343272
15.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
16.

[The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].

Cheng ZQ, Yin W, Fan JY, Ma TJ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Jun;24(3):306-9. Chinese.

PMID:
12905641
17.

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.

Choi HJ, Im JA, Kim SH.

Maturitas. 2008 Jun 20;60(2):170-6. doi: 10.1016/j.maturitas.2008.05.003. Epub 2008 Jun 24.

PMID:
18572334
18.

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ.

Aging (Milano). 2000 Feb;12(1):1-12.

PMID:
10746426
19.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
20.

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.

Clin Drug Investig. 2006;26(2):63-74.

PMID:
17163237
Items per page

Supplemental Content

Write to the Help Desk